Prolonged continuous infusion of low-dose rIL-2.

por Janssen, R. A., Buter, J., The, T. H., Mulder, N. H., de Leij, L.
Publicado 1994

Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.

por Janssen, R. A., Sleijfer, D. T., Heijn, A. A., Mulder, N. H., The, T. H., de Leij, L.
Publicado 1992

Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.

por Martens, A., Janssen, R. A., Sleijfer, D. T., Heijn, A. A., Mulder, N. H., The, T. H., de Leij, L.
Publicado 1993

Immunomodulatory effects of intravenous BIS-1 F(ab')2 administration in renal cell cancer patients.

por Janssen, R. A., Kroesen, B. J., Buter, J., Mesander, G., Sleijfer, D. T., The, T. H., Mulder, N. H., de Leij, L.
Publicado 1995

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

por Kroesen, B. J., Buter, J., Sleijfer, D. T., Janssen, R. A., van der Graaf, W. T., The, T. H., de Leij, L., Mulder, N. H.
Publicado 1994